Israeli breakthrough in non-invasive prostate cancer test
Want to cure prostate cancer? Try Israel’s worlds first non -invasive prostate cancer test innovation with 91.3% sensitivity.
In this fast-paced world, people are not giving much attention to their health. This is the reason that we see increased health issues across the globe. Digital healthcare platform is being implemented by hospitals in order to ease the eHealth services to patients. In the US, a great amount of Prostate biopsy is been noticed. Researchers say that one-fifth of these diagnosis results in cancer diagnosis. Doctors find it difficult to go through a traditional prostate cancer screening test, which involves a blood test to measure PSA-prostate specific antigen. Researchers are finding new ways for the non-invasive prostate test, which will eventually reduce the discomfort, stress, and expense of traditional methods.
Scientists from Israel have developed one such non-invasive technique to detect prostate cancer. Researchers at Kaplan Medical Centre, Rehovot have collaborated with Micromedic Technologies and developed CellDetect non-invasive prostate cancer test.
Scientists at Kalpan are working on this innovative technique from past two years. Cytopathological staining platform- Celldetect is a breakthrough in detecting prostate cancer cells as urine samples were recorded 91.3% sensitivity, considering 75% specificity. To prove its effectiveness, Celldetect was first used to diagnose cervical and bladder cancer, turned out to be very effective, and has been subjected to prostate cancer as well. The technology is now being considered to be used in the detection of additional cancer indications. Keren Gueta Milshtein- a biochemist and director of R&D at Micromedic Technologies said, “The cervical and bladder cancer diagnostic products are in initial commercial stages in the United States and Europe.”
Many screenings are being carried out for Celldetect test as researchers at Kalpan are worried about its efficiency. They do not want the test to deliver false positive results unlike many prostate screening tests with a specificity of just 25%.
Scientists are working hard to cure the second most common cancer amongst men, through Celldetect technique. To determine and know exactly when to offer a prostate cancer test, Prof. Dan Leibowitz, the chief of Urology and the Principal Investigator at Kaplan, reiterated the importance of using the new prostate cancer diagnostic tool in accurately detecting the cancer cells. He stressed that this would help in curbing the unnecessary tests, hence allowing patients to know when and whether to perform or avoid a prostate biopsy. During the initial tests, this innovative technology was accurate in detecting the cancer cells when compared to common PSA test.
Guy Lerner-CEO of Micromedic Company said, “With these clinical study results, we have the potential to transform prostate cancer diagnostics, offering patients a non-invasive, accurate and reliable test, and one that could improve the healthcare system through considerable cost savings.”
According to the company, this new technology can be used to detect a tumor at its early stages, which can greatly be missed by the standard staining techniques, and hence early treatment. However, the American Cancer Society mentioned on its site, “There are still questions about whether the benefits of screening outweigh the risks for most men.” It is expected that this new technology will help reduce cancer-related deaths worldwide, as the United States and Europe alone post 29,000 and 70,000 cancer-related deaths yearly.
image credit: http://www.m-medic.com/
